Safety (including all causes of mortality) in the test IVIg (Omr-IgG-am™) group versus the 2 placebo groups, as defined by the total number of serious adverse events regardless of relatedness to study drug administration.

Pharmacokinetics of specific anti-WNV antibodies as measured by ELISA and PRNT methods.

Proportion of patients returning to pre-morbid baseline at 3 months, between treated and untreated groups of patients with WNV infection, as assessed by two scoring systems the Barthel Index and the MRS.

(and 4 more...)

62

All

18 Years and older (Adult, Senior)

NCT00068055

03-107CASG 210

September 2003

December 2006

December 2006

September 8, 2003

February 7, 2011

University of Alabama at BirminghamBirmingham, Alabama, United States

University of South Alabama Medical CenterMobile, Alabama, United States

St. Joseph's Hospital and Medical CenterPhoenix, Arizona, United States